




# PHARMACEUTICAL 2023

Evolus Inc.  
Rank 322 of 446





RealRate

# PHARMACEUTICAL 2023

Evolus Inc.  
Rank 322 of 446



The relative strengths and weaknesses of Evolus Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evolus Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Evolus Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is -25%, being 68% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	100,802
Cost of Goods Sold	55,887
Intangible Assets	69,805
Liabilities, Current	46,509
Liabilities, Non-Current	1,224
Other Assets	4,760
Other Compr. Net Income	-337
Other Expenses	20,669
Other Liabilities	111,751
Other Net Income	110
Other Revenues	148,616
Property and Equipment	2,616
Research and Development	4,742
Selling, General and Administrative Expense	141,840

Output Variable	Value in 1000 USD
Assets	177,983
Liabilities	159,484
Expenses	223,138
Revenues	148,616
Stockholders Equity	18,499
Net Income	-74,412
Comprehensive Net Income	-74,580
Economic Capital Ratio	-25%